The Daily

Lilly says the FDA has approved Foundayo (orforglipron) — a once‑daily oral GLP‑1 receptor agonist — positioning it as the first GLP‑1 pill in the category. The company frames this as a scale story as much as a medical one: pills are simpler to ship, store, and start than injectables, and they lower the barrier for primary‑care prescribing. Lilly points to its Phase 3 program showing meaningful A1C reduction and weight loss, and it’s already talking about broad access and fast rollout. The near‑term question is execution: payer coverage, pricing, and whether real‑world adherence beats weekly injections. The long game is even bigger: if an oral GLP‑1 becomes “default,” it rewires how diabetes (and obesity) therapy is distributed globally.

Lilly is paying $6.3 billion upfront to acquire Centessa’s sleep‑disorder focused assets, per Fierce Biotech — another signal that big pharma is leaning hard into neurology despite clinical risk. The deal centers on a program aimed at sleep disorders, where differentiation is tough and trial endpoints can be messy. But if it works, the commercial surface area is huge: chronic conditions, large populations, and room for combination strategies. For Centessa, it’s an exit at scale; for Lilly, it’s a portfolio bet that neuroscience can be industrialized the way cardiometabolic has been.

Pharmaphorum reports the FDA has cleared Denali’s Hunter syndrome therapy, a milestone for a disease where treatment has historically struggled to reach the brain. The key claim is improved delivery into the central nervous system — the piece that matters for neurocognitive symptoms. Beyond the science, approvals in ultra‑rare disorders often become manufacturing and access problems: diagnosing patients, coordinating infusion logistics, and convincing payers on high per‑patient cost. If Denali’s approach holds up post‑launch, it’s also a platform signal for other lysosomal storage disorders where CNS penetration is the bottleneck.

AP notes the regular season is basically over in percentage terms: only 111 games remained league‑wide as the week started — about 91% of the schedule already played. The big picture is separation: five teams are eliminated in each conference, while a handful have essentially locked spots and everyone else is fighting for seeding and home court. AP highlights the East battle around the 6th seed (automatic playoff berth) versus the play‑in, plus key dates: April 14/15/17 for the play‑in and April 18/19 for playoff openers. This is the part of the season where a single back‑to‑back or rest decision changes matchups — and front offices quietly start optimizing for opponents.

CBS (via Field Level Media) frames the 76ers–Heat matchup as a classic late‑season swing game. Philadelphia is 41–33, sitting seventh but within a half‑game of sixth with eight games remaining — and sixth matters because it avoids the play‑in. The story’s detail that jumps out: Maxey returned from a finger tendon strain to log 43 minutes with 26 points, while Embiid is ramping up after missing 13 straight games (strained right oblique). Miami, meanwhile, had lost seven of eight entering the game. It’s not just drama — it’s scheduling, health, and tiebreakers hardening into bracket reality.

A new PubMed‑indexed paper (PMID 41380698) reports Phase 2 results combining epcoritamab with chemotherapy in Richter transformation — the aggressive lymphoma that can emerge from CLL and is notoriously hard to treat. The promise here is pragmatic: get patients to a deeper response fast enough to reach transplant or cellular therapy, without burning through lines that don’t move the needle. Even in small studies, Richter outcomes tend to be brutal; any regimen that meaningfully lifts response rates and buys time matters. What I’ll be watching is durability (not just “ORR”) and infection management, because bispecific‑plus‑chemo can be immunologically expensive.

ScienceDaily summarizes NIH‑supported work on a four‑marker blood panel for pancreatic ductal adenocarcinoma — the cancer with a roughly 10% five‑year survival because it’s usually caught late. The test combines two familiar biomarkers (CA19‑9 and THBS2) with two proteins elevated in early disease (ANPEP and PIGR). Reported performance: 91.9% accuracy across all stages with a 5% false‑positive rate, and 87.5% detection in stage I/II disease. The key implication isn’t “screen everyone tomorrow” — it’s whether the panel holds up in pre‑diagnostic cohorts (high‑risk patients) without triggering a cascade of unnecessary imaging.

ORF Radio Wien kuratiert die nächsten größeren Kultur‑Fixpunkte recht charmant: vom „Saturday Night Party Special“ rund um den ESC bis zu Konzert‑Gewinnspielen. Konkret genannt: Der Hot Pants Road Club spielt am 17. April im Wiener Metropol (XXL‑Format, 15‑köpfig). Und Peter Cornelius geht 2026 (75. Geburtstag) auf Tour — ein Reminder, dass Wien im April zwischen Pop‑Event und Nostalgie locker beides kann.

Die Stadt Wien bündelt die wichtigsten Frühjahrs‑Baustellen der Wiener Linien: Für 2026 sind 12,5 Kilometer Straßenbahngleise und 33 neue Weichen angekündigt. Im konkreten Alltag spürbar wird’s auf Klassikern wie der Lerchenfelder Straße: Linie 46 kann von 16. März bis Mitte Juli nicht zwischen Ring/Volkstheater und Thaliastraße fahren. Und ab 20. April beginnt die Sanierung auf Dornbacher Straße/Hernalser Hauptstraße (Linie 43) in zwei Phasen bis September. Quintessenz: Wer im April “komisch lange” unterwegs ist, ist vermutlich nicht langsam — die Stadt baut wirklich.

Reuters reports Anthropic has signed an agreement with the Australian government that combines two ideas usually kept separate: AI safety research and economic data tracking (how AI changes jobs, productivity, and risk). The interesting move is treating measurement as a safety tool — if you can’t see economic displacement early, you can’t govern it. This kind of partnership is also a tell: governments want a “responsible AI” narrative, and labs want legitimacy and policy influence in return. The open question is transparency: what gets published, what stays internal, and how independent the evaluation really is.

CNBC profiles Nebius’ plan to build an AI‑focused compute site in Finland, leaning on stable power and cooler climate for datacenter economics. The subtext: in 2026, compute isn’t just chips — it’s land, grid access, cooling, and permitting. Europe’s pitch is clean energy and proximity to regulated customers; the risk is that bottlenecks (transformers, interconnect, power contracts) move slower than model demand. If Europe wants sovereignty in AI, it’s going to look a lot like boring infrastructure.

Utility Dive reports a wave of large‑load tariffs as U.S. states and utilities try to manage data‑center power demand without sticking everyone else with the bill. The policy logic is simple: if a single customer wants a massive interconnection and steady load, they should pay for grid upgrades and risk. The implication is less simple: pricing structures start to decide where AI clusters physically live. In 2026, “AI policy” increasingly looks like rate cases, not just model rules.

Wer in den Osterferien einen „Indoor‑Plan“ braucht: Die Playworld Wien fährt laut Mamilade ein fixes Ferien‑Programm mit Kuscheltier‑Werkstatt (Set: € 29,90; Outfit pro Teil € 12) plus Basteln/Kinderschminken. Termine u.a. 3.–5. April jeweils 11:00–17:00; geöffnet ist in der Ferien‑Woche meist 10:00–19:00. Dazu gibt’s eine kleine „Oster‑Entdecker‑Mission“ mit fünf versteckten Objekten und Mini‑Überraschung. Kein Geheimtipp, aber extrem planbar — und das ist manchmal das ganze Spiel.

Das ZOOM Kindermuseum listet die Lange Nacht der Forschung 2026 als Kinder‑Sonderveranstaltung: 24. April, von 17 bis 23 Uhr, an über 270 Standorten in ganz Österreich. Für Familien ist das ein selten guter Mix aus „Darf ich anfassen?“ und echten Labors/Workshops — ohne dass man den ganzen Abend in einem Raum festhängt. Praktischer Tipp: früh entscheiden, welcher Ort Priorität hat; die Auswahl ist so groß, dass man sonst nur pendelt.

The BBC reports another delay in the EU’s Entry/Exit System (EES) rollout at Dover and Eurotunnel, citing ongoing technical issues with French systems. The practical detail: from April 10, airports are still set to fully implement biometric checks — and in the meantime, passengers can be asked for additional information at border control even without biometrics. EES is meant to replace passport stamping and track overstays across the 29‑country Schengen Area. Translation for travelers: build buffer time, and assume the “new process” will arrive in phases, not as a clean switch.

Aviation Week’s April routes roundup is a good reminder that “summer schedule” is basically infrastructure. Highlights: Alaska Airlines will start daily Seattle–Rome on April 28 (Boeing 787‑9), upgraded from 4x weekly due to demand. And for Vienna specifically, China Eastern is set to launch Xi’an–Vienna service on April 20, marking its first route to the Austrian capital. The subtle geopolitical note: Europe–Asia growth is being shaped by airspace access — and that is now a competitive advantage, not a footnote.